about
Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission.High-sensitivity C-reactive protein: an independent risk factor for left ventricular hypertrophy in patients with lupus nephritis.Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomesLong-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study.Association of Relapse with Renal Outcomes under the Current Therapy Regimen for IgA Nephropathy: A Multi-Center Study.Up-regulation of Serum MiR-130b-3p Level is Associated with Renal Damage in Early Lupus Nephritis.Serum Renalase Levels Correlate with Disease Activity in Lupus Nephritis.Urgent-Start Peritoneal Dialysis and Hemodialysis in ESRD Patients: Complications and Outcomes.Association between the levels of urine kidney injury molecule-1 and the progression of acute kidney injury in the elderly.Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis.Kidney injury molecule-1 in acute kidney injury and renal repair: a review.High urinary excretion of kidney injury molecule-1 predicts adverse outcomes in acute kidney injury: a case control study.NLRP3 inflammasome mediates contrast media-induced acute kidney injury by regulating cell apoptosis.L-FABP: A novel biomarker of kidney disease.Renoprotective mechanisms of Astragaloside IV in cisplatin-induced acute kidney injury.Kidney Injury Molecule-1 is Elevated in Nephropathy and Mediates Macrophage Activation via the Mapk Signalling Pathway.MiR-155 is Involved in Renal Ischemia-Reperfusion Injury via Direct Targeting of FoxO3a and Regulating Renal Tubular Cell Pyroptosis.Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost-effectiveness analysis.High Peritoneal Glucose Exposure Is Associated with Increased Incidence of Relapsing and Recurrent Bacterial Peritonitis in Patients Undergoing Peritoneal Dialysis.Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis.Diagnostic performance of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for acute kidney injury in an obstructive nephropathy patient.Hepatocyte growth factor ameliorates progression of interstitial injuries in tubular epithelial cells.Keto acid-supplemented low-protein diet for treatment of adult patients with hepatitis B virus infection and chronic glomerulonephritis.Predicting mortality in microscopic polyangiitis with renal involvement: a survival analysis based on 64 patients.Protein Kinase A/CREB Signaling Prevents Adriamycin-Induced Podocyte Apoptosis via Upregulation of Mitochondrial Respiratory Chain Complexes.[Expression of c-met in human kidney fibroblasts induced by high glucose in vitro and the regulation of Radix Astragali].Calcium dobesilate may alleviate diabetes‑induced endothelial dysfunction and inflammation.Functional metabotropic glutamate receptors 1 and 5 are expressed in murine podocytes.FEASIBILITY OF URGENT-START PERITONEAL DIALYSIS IN OLDER PATIENTS WITH END-STAGE RENAL DISEASE: A SINGLE-CENTER EXPERIENCE.Role of Immune Cells in Diabetic Kidney Disease.Quantitative parameters of contrast-enhanced ultrasonography for assessment of renal pathology: A preliminary study in chronic kidney disease.Contrast-enhanced ultrasonography for assessment of tubular atrophy/interstitial fibrosis in immunoglobulin A nephropathy: a preliminary clinical study.Change in cardiovascular disease status in peritoneal dialysis patients: a 5-year single-center experience.Urinary retinol-binding protein as a risk factor of poor prognosis in acute-on-chronic renal injury.A case of ureteral myeloid sarcoma post-renal transplantation.Prediction of Tubulointerstitial Injury in Chronic Kidney Disease Using a Non-Invasive Model: Combination of Renal Sonography and Laboratory Biomarkers.The role of hemoglobin variability as a prognostic indicator in peritoneal dialysis patients: a retrospective descriptive study.[Diagnostic value of CT peritoneography for non-infectious complications of peritoneal dialysis].Clinical Predictors of Response to Prednisone Plus Cyclophosphamide in Patients with Idiopathic Membranous Nephropathy.
P50
Q33906377-1462F63F-FA4B-414D-9B60-8CA5B51F136AQ34284706-DEB28178-5579-430F-ADF9-BE15216DB696Q34525437-0375EA27-F35C-4F0D-81CA-A1E12CB75DDBQ35743170-CFEFF061-51F7-4D9A-95A8-F2A3EC83A127Q35775659-751D237C-4905-413A-8D63-3E2FD9E7B5BEQ36002595-8B84AFE2-BCD0-4E27-A56F-359D1EB33CE0Q36117084-1FBBAC3D-9287-465C-BDC8-9A4731E9C5F9Q36185838-6EEA51FE-0185-400F-9D31-9ADD4ACA84F2Q36276863-407A51E7-886E-40DF-B6D5-694DC53E80FCQ37128891-F7F4DAC9-6CBF-4CEC-B5AA-9899BB1D8D2FQ37159624-4A617880-216A-42E0-B848-CE75F032DDCCQ37246209-8C5344F2-9749-4ABB-83F0-3E8A49906A31Q37323893-BD1E4037-818A-411D-9F75-F9FF26BF2355Q38386994-6E268FA0-4A75-455B-990B-27C2D5342B43Q38657164-621057C6-232D-47B7-86CC-E24929558AC5Q38715872-170FF5E9-10D8-471D-AB88-90FFA4AD7807Q38724761-6F289F6E-ECCD-4D94-A8DB-CBEA07A99E75Q38906326-F42FCF96-0A62-4D8A-8F67-EBB92C6CD793Q41126314-94618C79-9E8E-4219-B889-35EAFB1C5145Q41471646-8667225E-3D9E-4D68-A7BA-95112AF02628Q41810678-9A92ADB0-3365-4844-8DB7-295C4F264C1AQ42259357-BAF0EB76-AD25-4A38-87A0-C7DF91BE55F2Q43225866-2DF82A1F-40FB-418B-B898-33D41A245687Q45351758-646B5BA6-0416-4439-9563-81380C765D3BQ45396216-5CB082A1-07D7-4CEA-B2CC-106BF6515FCCQ46283689-E797D31B-4DAF-464C-AFB0-D9FC7CF9C0FAQ46601807-5F5277A3-D6CE-483D-B82E-D833EF4BC54BQ47641666-A97D9FD1-152A-42EB-BC3E-525861235700Q48783985-3D76AB0B-D8B3-455E-8232-ADDEC2535DB6Q49834235-B3DB7461-4EDC-4B4E-A1DD-151F40A1506AQ49985908-CC2F627C-4443-4F9D-BAEC-62ABC4923C54Q50075154-060DAE36-267F-4144-AAD3-0521A8FE503BQ50129910-0B67747C-6C04-4091-8A98-3F90D95A7B76Q50991537-406E5609-383D-4B2D-A4DB-DC867F6A6784Q51657788-FBF30D8F-50C2-4374-B6FF-FEA39C6E8416Q52682748-779DC2FE-6648-414D-B0C1-657032E38D84Q52729002-BCC08248-D2E8-4A8E-87AD-C105C5A14C15Q52822329-221726E4-2C37-4ACF-B2A3-1510C294D4C9Q53417605-764B199D-6D69-4D15-A285-D0C6C4610274Q53542801-1BA0D449-9626-4F9F-9307-09A769164D0A
P50
description
investigador
@es
researcher
@en
name
Shan Mou
@en
type
label
Shan Mou
@en
prefLabel
Shan Mou
@en
P31
P496
0000-0003-4160-1681